Israel Biotech Fund — Full Portfolio

BiotechTel Aviv

Ran Oren(Director)Tali Gorfine(Executive Officer)Carol Brosgart(Director)Yohai Stenzler(Executive Officer)Liat Hayardeny(Executive Officer)Shmuel Nir(Director)

Board seatDavid Sidransky· per SEC Form D · $350K raise · filed Aug 2017

BiotechYavne

Ety Klinger(Executive Officer, Director)Ofer Gonen(Executive Officer)Boaz Gur-Lavie(Chief Financial Officer)Sharon Malka(Director)Vickie R. Driver(Director)Tzvi Palash(Executive Officer)

AION Labs is a venture studio that creates AI, technology, and science startups focused on pharmaceutical R&D, using a co-development model that gives startups access to pharma expertise, validation opportunities, and pre-seed funding.

AI & Machine LearningBiotechDeep Tech

Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall.

BiotechHealthtechMedical Devices

Avner Geva(CEO, Co-founder)Avi Eftel(CTO, Co-founder)Roger R. Dmochowski(CMO)Ken Berlin(Executive Chairman)

BiotechMonmouth Junction, US

Samir Khleif(Director)Richard Berman(Director)Igor Gitelman(Director)Andres Gutierrez(Executive Officer)Roni Appel(Director)Kenneth Berlin(Executive Officer, Director)

Board seatDavid SidranskyYuval Cabilly· per SEC Form D · $433.8K raise · filed Nov 2023

Orgenesis operates the POCare Platform for developing, scaling, and commercializing advanced cell and gene therapies delivered at the point of care.

BiotechHealthtechMedical DevicesGermantown, US

Etti Hanochi(Director)Yaron Adler(Director)Yachin Yachin(Director)Neil Reithinger(Executive Officer)Vered Caplan(Executive Officer, Director)Ferber Ferber(Executive Officer)

Board seatDavid Sidransky· per SEC Form D · $10M raise · filed Dec 2015

BiotechSan Diego, US

Fred Knoll(Director)Patrick Ostronick(Director)John Brancaccio(Director)Jamie Sulley(Executive Officer, Director)Paul Weiss(Director)Joanne Barsa(Executive Officer)

Board seatDavid Sidransky· per SEC Form D · $800K raise · filed Sep 2015

4C Biomed develops immuno-oncology therapies using a patient-derived discovery platform that identifies novel immune targets from autologous cancer and immune cell systems.

BiotechHealthtech

BioSpace is a platform providing news, job listings, and recruitment marketing solutions for the life sciences industry.

BiotechHealthtechHR TechMarketing TechMedia & EntertainmentMedical DevicesSaaSDes Moines, US

Josh Goodwin(CEO)

Ayala Pharma is associated with pharmaceutical drug candidates including AL102, AL101, and BST-236; the page states that AL102 and AL101 were acquired by Immunome, Inc. in Q1 2024.

Biotech

Gamida Cell develops allogeneic cell therapy products using its proprietary nicotinamide (NAM) technology to enhance and expand cells for treating patients with hematologic and non-hematologic conditions.

BiotechHealthtechLongevity

Nectin is a biotech developing a pipeline of targeted immunotherapies, including immuno-oncology antibodies and antibody-drug conjugates (ADCs).

BiotechMedical Devices

SpliSense develops RNA-based therapies using antisense oligonucleotides (ASOs) to restore and modify protein function.

BiotechHealthtech

Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform.

AI & Machine LearningBiotechDigital HealthMountain View, US

Judith Weiss Paltiel(PhD, VP Development)Anat Binur(Executive Officer, Director)Yanay Ofran(Director)Scott Brady(Director)

BoardSamir Kaul(Director)